Acadia Pharmaceuticals Inc. reported strong financial results for the fourth quarter and full year 2023, with total net product sales of $726.4 million, reflecting a 40% revenue growth. The company saw fourth quarter DAYBUE™ net product sales of $87.1 million and full year net product sales of $177.2 million, along with fourth quarter NUPLAZID® net product sales of $143.9 million and full year net product sales of $549.2 million. The company also highlighted advancements in its pipeline, including the initiation of Phase 3 trials for ACP-101 in Prader-Willi syndrome and ACP-204 in Alzheimer's disease psychosis. Acadia Pharmaceuticals is optimistic about its future prospects and is set to announce top-line results from the ADVANCE-2 study by the end of the first quarter.
Acadia, page-220
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$20.98 |
Change
-0.110(0.52%) |
Mkt cap ! $2.670B | |||
| Open | High | Low | Value | Volume |
| $21.10 | $21.11 | $20.45 | $3.650M | 175.0K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 28 | $20.98 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $20.99 | 372 | 11 |
View Market Depth
| Last trade - 15.08pm 20/05/2024 (20 minute delay) ? |
|
|||||
|
Last
$20.92 |
Change
-0.110 ( 1.07 %) |
||||
| Open | High | Low | Volume | ||
| $21.11 | $21.11 | $20.45 | 75478 | ||
| Last updated 15.28pm 20/05/2024 ? | |||||
| NEU (ASX) Chart |